Inventiva S.A. (LON:0RNK)
3.170
-0.060 (-1.86%)
Apr 24, 2025, 1:25 PM BST
Inventiva Employees
As of December 31, 2024, Inventiva had 118 total employees, including 114 full-time and 4 part-time employees. The number of employees decreased by 5 or -4.07% compared to the previous year.
Employees
118
Change (1Y)
-5
Growth (1Y)
-4.07%
Revenue / Employee
100.48K GBP
Profits / Employee
-1.31M GBP
Market Cap
258.05M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 94,300 |
GSK plc | 68,629 |
Haleon | 24,561 |
Smith & Nephew | 17,349 |
ConvaTec Group | 10,489 |
Hikma Pharmaceuticals | 9,500 |
HUTCHMED (China) | 1,811 |
Oxford Nanopore Technologies | 1,315 |
Inventiva News
- 23 days ago - Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis - GlobeNewsWire
- 4 weeks ago - Inventiva S.A. (IVA) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Inventiva reports its 2024 full year results and provides a business update - GlobeNewsWire
- 5 weeks ago - Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results - GlobeNewsWire
- 2 months ago - Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment - GlobeNewsWire
- 2 months ago - Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial - GlobeNewsWire
- 2 months ago - Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update - GlobeNewsWire
- 3 months ago - Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology - GlobeNewsWire